These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 31464511

  • 1. A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings.
    Childress AC, Cutler AJ, Marraffino A, McDonnell MA, Turnbow JM, Brams M, DeSousa NJ, Incledon B, Sallee FR, Wigal SB.
    J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):2-14. PubMed ID: 31464511
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR, Wilens TE, Bostrom S, Arnold VK, Marraffino A, Cutler AJ, López FA, DeSousa NJ, Sallee FR, Incledon B, Newcorn JH.
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study.
    Childress AC, Brams MN, Cutler AJ, Donnelly GAE, Bhaskar S.
    J Child Adolesc Psychopharmacol; 2020 Dec; 30(10):580-589. PubMed ID: 33090921
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
    Wigal SB, Childress A, Berry SA, Belden H, Walters F, Chappell P, Sherman N, Orazem J, Palumbo D.
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):690-699. PubMed ID: 28557548
    [Abstract] [Full Text] [Related]

  • 5. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.
    Childress AC, Kollins SH, Cutler AJ, Marraffino A, Sikes CR.
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):66-74. PubMed ID: 27183299
    [Abstract] [Full Text] [Related]

  • 6. Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC, Kando JC, King TR, Pardo A, Herman BK.
    J Child Adolesc Psychopharmacol; 2019 Feb; 29(1):2-8. PubMed ID: 30575407
    [Abstract] [Full Text] [Related]

  • 7. A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder.
    Kollins SH, Braeckman R, Guenther S, Barrett AC, Mickle TC, Oh C, Marraffino A, Cutler AJ, Brams MN.
    J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):597-609. PubMed ID: 34714120
    [Abstract] [Full Text] [Related]

  • 8. Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of attention, behavior, and performance benefits in children with attention-deficit/hyperactivity disorder.
    Silva RR, Brams M, McCague K, Pestreich L, Muniz R.
    Clin Neuropharmacol; 2013 Nov; 36(4):117-21. PubMed ID: 23860345
    [Abstract] [Full Text] [Related]

  • 9. NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.
    Wigal SB, Childress AC, Belden HW, Berry SA.
    J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):3-10. PubMed ID: 23289899
    [Abstract] [Full Text] [Related]

  • 10. The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study.
    Childress AC, Brams M, Cutler AJ, Kollins SH, Northcutt J, Padilla A, Turnbow JM.
    J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):402-14. PubMed ID: 25692608
    [Abstract] [Full Text] [Related]

  • 11. Symptomatic and Functional Response and Remission From the Open-Label Treatment-Optimization Phase of a Study With DR/ER-MPH in Children With ADHD.
    Childress AC, Cutler AJ, Po MD, DeSousa NJ, Warrington LE, Sallee FR, Incledon B.
    J Clin Psychiatry; 2021 Jun 22; 82(4):. PubMed ID: 34166587
    [Abstract] [Full Text] [Related]

  • 12. A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder.
    Wigal SB, Greenhill LL, Nordbrock E, Connor DF, Kollins SH, Adjei A, Childress A, Stehli A, Kupper RJ.
    J Child Adolesc Psychopharmacol; 2014 Dec 22; 24(10):562-9. PubMed ID: 25470572
    [Abstract] [Full Text] [Related]

  • 13. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ, COMACS Study Group.
    Pediatrics; 2004 Mar 22; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [Abstract] [Full Text] [Related]

  • 14. A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.
    Brams M, Muniz R, Childress A, Giblin J, Mao A, Turnbow J, Borrello M, McCague K, Lopez FA, Silva R.
    CNS Drugs; 2008 Mar 22; 22(8):693-704. PubMed ID: 18601306
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder.
    Silva RR, Muniz R, Pestreich L, Childress A, Brams M, Lopez FA, Wang J.
    J Child Adolesc Psychopharmacol; 2006 Jun 22; 16(3):239-51. PubMed ID: 16768632
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day.
    Faraone SV, Childress AC, Gomeni R, Rafla E, Kando JC, Dansie L, Naik P, Pardo A.
    J Child Adolesc Psychopharmacol; 2023 Feb 22; 33(1):14-19. PubMed ID: 36730749
    [Abstract] [Full Text] [Related]

  • 17. Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and D,L-methylphenidate and placebo in a laboratory classroom setting.
    Silva R, Muniz R, McCague K, Childress A, Brams M, Mao A.
    Psychopharmacol Bull; 2008 Feb 22; 41(1):19-33. PubMed ID: 18362868
    [Abstract] [Full Text] [Related]

  • 18. Effect of Delayed-Release and Extended-Release Methylphenidate on Caregiver Strain and Validation of Psychometric Properties of the Caregiver Strain Questionnaire: Results from a Phase 3 Trial in Children with Attention-Deficit/Hyperactivity Disorder.
    López FA, Faraone SV, Newcorn JH, Doll HA, Rhoten S, Lewis HB, Khan TF, DeSousa NJ, Sallee FR, Incledon B.
    J Child Adolesc Psychopharmacol; 2021 Apr 22; 31(3):179-186. PubMed ID: 33797983
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.
    Muniz R, Brams M, Mao A, McCague K, Pestreich L, Silva R.
    J Child Adolesc Psychopharmacol; 2008 Jun 22; 18(3):248-56. PubMed ID: 18582179
    [Abstract] [Full Text] [Related]

  • 20. Model-Based Approach for Establishing the Predicted Clinical Response of a Delayed-Release and Extended-Release Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder.
    Gomeni R, Komolova M, Incledon B, Faraone SV.
    J Clin Psychopharmacol; 2020 Jun 22; 40(4):350-358. PubMed ID: 32590405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.